Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms

Summary

P276-00 is a molecule derived from Rohitukine, which through pre clinical assays was identified as a selective Cdk4-D1 and Cdk1-B inhibitor.The inhibition of these Cdks causes cell cycle arrest between the G1-S transition thus blocking the cell cycle events at an early stage of development. It therefore has the potential for being efficacious with lesser side effects.

Timeline

Start

2006-03

Primary completion

2008-08

Completion

2008-10

Outcome

Outcome not reported

Stopped: “The decision to terminate this study after 202 mg/m2 cohort was taken as MTD achieved in other study at 185 mg/m2”

Drugs

Indications